Washingtonians share how they afford pricey weight loss medications
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...
WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...
Health plans at 1 in 5 large companies cover weight-loss drugs for employees
Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...
Medicare coverage of weight loss drugs would cost $35B: CBO
Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...
Offering Wegovy and other weight loss drugs on Medicare could cost $35 billion
Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...
Only 1 in 5 Large Companies' Health Plans Cover New Weight-Loss Meds for Employees
WEDNESDAY, Oct. 9, 2024 (HealthDay News) -- When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and ...
Your employer may start covering weight-loss drugs soon
Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, ...
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...
Companies are more willing to consider covering weight-loss drugs
That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
Physicians Committee5d
Despite Heavy Marketing, Most Americans Reject the New Weight-Loss Drugs
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...